NCT06864052View on ClinicalTrials.gov

The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation

NANot yet recruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2029

Conditions

StrokeAtrial Fibrillation

Interventions

DRUG

Administration of Apixaban

Apixaban 2.5mg BID or Apixaban 5mg BID

DRUG

Administration of Edoxaban

Edoxaban 15mg QD or Edoxaban 30mg QD or Edoxaban 60mg QD

Trial Locations (1)

07804

Ewha Womans University Medical Center, Seoul

All Listed Sponsors

lead

Ewha Womans University Seoul Hospital

OTHER

NCT06864052 - The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation | Biotech Hunter | Biotech Hunter